Evidence map›Paper›PMID 15121510›Full record

Trial reportEnvironmental health perspectives2004

Human consumption of methyleugenol and its elimination from serum.

Arnold Schecter, George W Lucier, Michael L Cunningham, Kamal M Abdo, Greg Blumenthal, Andrew G Silver, Ron Melnick, Christopher Portier, Dana B Barr, John R Barr and 7 more

Open access · diamondAbstract readClinical Trial
In one paragraph

Trial report in Environmental health perspectives, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 2 countries.

Arnold SchecterUniversity of Texas School of Public Health, Regional Campus at Dallas, 75390, USA. arnold.schecter@utsouthwestern.edu
George W Lucier
Michael L Cunningham
Kamal M Abdo
Greg Blumenthal
Andrew G Silver
Ron Melnick
Christopher Portier
Dana B Barr
John R Barr
Stephen B Stanfill
Donald G Patterson
Larry L Needham
Woodhall Stopford
Scott Masten
Jill Mignogna
Kuang Chi Tung
University of Texas Health Science Center at Dallas · US

Funding

Statistical Models In Toxicology And BiochemistryZIAES048002 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI PORTIER, CHRISTOPHER J · 2009 to 2010
$2.9M
STATISTICAL MODELS IN TOXICOLOGY AND BIOCHEMISTRYZ01ES048002 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI PORTIER, CHRISTOPHER J · 1988 to 2008
$2.8M
METABOLISM AND MUTAGENICITY OF MUTAGENIC NONCARCINOGENSZ01ES021119 · NIEHS · ENVIRONMENTAL HEALTH SCIENCES · PI CUNNINGHAM, MICHAEL · 1990 to 2007
$372k
6 · The paper itself

Abstract

Under a mandate from the U.S. Congress, the National Toxicology Program (NTP) of the U.S. Department of Health and Human Services conducts animal bioassays for carcinogenicity of potentially toxic chemicals to which the U.S. population might be exposed. Methyleugenol, a natural as well as synthesized substance, was nominated for study because it is structurally similar to safrole, a known animal carcinogen. Methyleugenol was found to be a very potent multisite carcinogen in male and female F344/N rats and B6C3F1 mice at all doses tested in 2-year NTP bioassays using gavage dosing. For this reason, human toxicokinetic studies were added to the traditional NTP protocol. A commercial brand of gingersnaps was found by chemists at the Centers for Disease Control and Prevention to contain a relatively high concentration of methyleugenol. After thorough scientific and clinical review, and approval by a National Institutes of Health institutional review board for the protection of human subjects, a study was conducted with nine healthy adult male and female human volunteers. The volunteers were given 12 gingersnaps for breakfast. Blood was drawn immediately before the meal and at 15, 30, 60, and 120 min afterward. The mean +/- SD fasting level of methyleugenol in serum was 16.2 +/- 4.0 pg/g wet weight. Peak blood levels were found at 15 min (mean +/- SD, 53.9 +/- 7.3 pg/g wet weight), followed by a rapid decline; the half-life of elimination was about 90 min. The peak levels were within the range of methyleugenol blood levels in the U.S. population, as measured concurrently in a subset of nonfasting participants in the Third National Health and Nutrition Examination Survey (NHANES III).

Indexed as

Food ContaminationAdministration, OralAdultCarcinogensDietEugenolFemaleHumansMaleMiddle AgedCarcinogensEugenolmethyleugenol

Identifiers

PMID15121510
PMCPMC1241961
OpenAlexW2034383839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.